U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review Read more about U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension Read more about Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM Read more about Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study Read more about Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal Read more about Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival Read more about New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo Read more about Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study Read more about First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC Read more about BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
Impulse Dynamics®’ INTEGRA-D Trial Completes Efficacy Phase Read more about Impulse Dynamics®’ INTEGRA-D Trial Completes Efficacy Phase
